The clinical trial, conducted across three Canadian sites including the McGill University Health Center, evaluated 11 patients maintained on standard opioid therapy. Data indicated that 91% of participants successfully reached a stable dose of Trichomylin through individualized titration. Among the evaluable subset, patients reported clinically relevant improvements in pain interference, fatigue, and sleep quality, suggesting a broader quality-of-life benefit beyond simple analgesia.

A key finding centered on the drug's interaction with standard care. While all participants were prescribed opioids for breakthrough pain, 28% of the evaluable group required no rescue medication during the study. Furthermore, rescue opioid use dropped from approximately 79% during the titration phase to 6% once patients reached stable dosing. These results align with recent FDA draft guidance prioritizing the development of non-opioid alternatives that limit patient exposure to addictive pain management therapies.

ZYUS management confirmed plans to advance Trichomylin into larger randomized controlled trials, intending to establish opioid-reduction as a co-primary endpoint. The company will present its findings at the Montreal International Palliative Care Congress later this month, marking a significant milestone in its effort to position Trichomylin as a viable alternative to conventional NSAIDs and opioids.